The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
MET overexpression as a promising therapeutic target in non-small cell lung cancer with acquired resistance to EGFR TKIs.
Xuchao Zhang
No relevant relationships to disclose
Jinji Yang
No relevant relationships to disclose
Huajun Chen
No relevant relationships to disclose
Zhi Xie
No relevant relationships to disclose
Qing Zhou
No relevant relationships to disclose
Jian Su
No relevant relationships to disclose
Hai-Yan Tu
No relevant relationships to disclose
Zhen Wang
No relevant relationships to disclose
Chongrui Xu
No relevant relationships to disclose
Yisheng Huang
No relevant relationships to disclose
Ben-Yuan Jiang
No relevant relationships to disclose
Bin-Chao Wang
No relevant relationships to disclose
Xiao-Yan Bai
No relevant relationships to disclose
Yi-Long Wu
No relevant relationships to disclose